UTMDNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
UTAH MEDICAL PRODUCTS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$74.55+0.04 (+0.05%)
Close on Oct 19, 2026
- Market cap
- $237.37M
- P/E (TTM)
- 22.7
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
57.1%−3.5 pts over 5 years
Operating margin
29.6%−2.9 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -5.8% | -9.7% | -1.8% | -0.4% | |
| Gross profit | -8.9% | -11.9% | -2.9% | -0.9% | |
| Operating income | -16.1% | -16.8% | -3.6% | -3.1% | |
| EPS, diluted | -12.1% | -8.3% | +3.4% | +1.0% | |
| Free cash flow | -1.9% | -11.0% | -5.8% | +0.5% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Current ratio | 11.41 | 16.42 | 37.62 | |
| Debt to equity | – | – | 0.00 | |
| Inventory turnover | 3.6× | 2.5× | 2.0× | |
| Capex to revenue | 8.4% | 2.0% | 1.0% | |
| Diluted shares | 4M | 4M | 3M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Utah Medical Products generated $94.15M from operations and spent $60.57M on capital expenditure, dividends and share buybacks. 4% of that went back into the business.
Generated
$94.15M
Used
$60.57M
Capital expenditure$2.60M4%Dividends$27.15M45%Share buybacks$30.82M51%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
5of 6 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero–
- Cash generatingOperating cash flow above zero$14.69M
- Return on assets improvedROA up on the prior year– → –
- Earnings backed by cashOperating cash flow above net income$14.69M vs –
- Less leverageLong-term debt to assets fell0.2% → 0.2%
- Better liquidityCurrent ratio rose25.64 → 37.62
- No dilutionShare count did not rise4M → 3M
- Gross margin improvedGross margin up on the prior year59.03% → 57.12%
- More efficientAsset turnover rose0.30 → 0.31